MedTrace Logo

BAttLe Against COVID-19 Using MesenchYmal Stromal Cells

NCT04348461 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-03-17

No results posted yet for this study

Summary

The investigational medicinal product consists of expanded allogeneic mesenchymal stromal cells derived from adipose tissue and administered intravenously.

The objective of this project is to evaluate the safety and efficacy of the administration of expanded allogeneic adipose tissue adult mesenchymal stem cells, in patients infected with SARS-COV-2 with COVID-19 type complications.

Conditions

  • COVID
  • Respiratory Distress Syndrome

Interventions

DRUG

Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells

Two serial doses of 1.5 million adipose-tissue derived mesenchymal stem cells per kg

Sponsors & Collaborators

  • Instituto de Investigación Sanitaria y Biomédica de Alicante

    collaborator NETWORK

  • Hospital General Universitario Gregorio Marañon

    collaborator OTHER

  • Clinica Universidad de Navarra, Universidad de Navarra

    collaborator OTHER

  • University of Salamanca

    collaborator OTHER

  • Hospital General Universitario de Alicante

    collaborator OTHER

  • Hospital Universitario Virgen de la Arrixaca

    collaborator OTHER

  • Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-06
Primary Completion
2020-09-15
Completion
2021-09-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04348461 on ClinicalTrials.gov